Literature DB >> 30066282

Support available for and perceived priorities of people with polymyalgia rheumatica and giant cell arteritis: results of the PMRGCAuk members' survey 2017.

Sara Muller1, Anne O'Brien2,3, Toby Helliwell2, Charles A Hay2, Kate Gilbert4, Christian D Mallen2, Kathryn Busby4.   

Abstract

Polymyalgia rheumatica and giant cell arteritis are relatively common, but under research inflammatory rheumatological conditions. This survey aimed to ascertain the matters in which patients feel they need support with these conditions and appraise how the Charity PMRGCAuk currently supports these needs and could do so in the future. PMRGCAuk members (n = 910) were invited to complete an on-line survey. The survey requested the respondent's history of PMR and or GCA, their perceived priorities for support for people with PMR and or GCA and views on the services already provided by the Charity. A total of 209 people completed the survey. Less than 24% had heard of either PMR or GCA before their diagnosis. Priorities in supporting people with PMR and or GCA included: being on and tapering off glucocorticoids (76.6%), specifically, length of treatment and the risks versus benefits and managing side effects. Respondents generally reported satisfaction with the services currently provided by PMRGCAuk. The support provided by PMRGCAuk is very helpful to members and fills an important gap in provision for people with PMR and or GCA. The areas in which the greatest proportions of participants requested support do not have an evidence base to underpin them. It is incumbent on the research community to address patients' concerns and provide an evidence base where it is required by those affected.

Entities:  

Keywords:  Giant cell arteritis; Patient involvement; Polymyalgia rheumatica

Mesh:

Substances:

Year:  2018        PMID: 30066282     DOI: 10.1007/s10067-018-4220-1

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  9 in total

Review 1.  Polymyalgia rheumatica.

Authors:  Miguel A González-Gay; Eric L Matteson; Santos Castañeda
Journal:  Lancet       Date:  2017-07-31       Impact factor: 79.321

2.  Polymyalgia rheumatica in primary care: a cohort study of the diagnostic criteria and outcome.

Authors:  Kevin Barraclough; William G Liddell; Jennifer du Toit; Christopher Foy; Bhaskar Dasgupta; Mike Thomas; William Hamilton
Journal:  Fam Pract       Date:  2008-08-07       Impact factor: 2.267

3.  The lifetime risk of adult-onset rheumatoid arthritis and other inflammatory autoimmune rheumatic diseases.

Authors:  Cynthia S Crowson; Eric L Matteson; Elena Myasoedova; Clement J Michet; Floranne C Ernste; Kenneth J Warrington; John M Davis; Gene G Hunder; Terry M Therneau; Sherine E Gabriel
Journal:  Arthritis Rheum       Date:  2011-03

Review 4.  Giant cell arteritis and polymyalgia rheumatica: current challenges and opportunities.

Authors:  Christian Dejaco; Elisabeth Brouwer; Justin C Mason; Frank Buttgereit; Eric L Matteson; Bhaskar Dasgupta
Journal:  Nat Rev Rheumatol       Date:  2017-09-14       Impact factor: 20.543

5.  Brief Report: A Prospective Open-Label Phase IIa Trial of Tocilizumab in the Treatment of Polymyalgia Rheumatica.

Authors:  Lindsay Lally; Lindsy Forbess; Christopher Hatzis; Robert Spiera
Journal:  Arthritis Rheumatol       Date:  2016-10       Impact factor: 10.995

Review 6.  Polymyalgia Rheumatica and Giant Cell Arteritis: A Systematic Review.

Authors:  Frank Buttgereit; Christian Dejaco; Eric L Matteson; Bhaskar Dasgupta
Journal:  JAMA       Date:  2016-06-14       Impact factor: 56.272

7.  Trial of Tocilizumab in Giant-Cell Arteritis.

Authors:  John H Stone; Katie Tuckwell; Sophie Dimonaco; Micki Klearman; Martin Aringer; Daniel Blockmans; Elisabeth Brouwer; Maria C Cid; Bhaskar Dasgupta; Juergen Rech; Carlo Salvarani; Georg Schett; Hendrik Schulze-Koops; Robert Spiera; Sebastian H Unizony; Neil Collinson
Journal:  N Engl J Med       Date:  2017-07-27       Impact factor: 91.245

8.  2015 Recommendations for the management of polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative.

Authors:  Christian Dejaco; Yogesh P Singh; Pablo Perel; Andrew Hutchings; Dario Camellino; Sarah Mackie; Andy Abril; Artur Bachta; Peter Balint; Kevin Barraclough; Lina Bianconi; Frank Buttgereit; Steven Carsons; Daniel Ching; Maria Cid; Marco Cimmino; Andreas Diamantopoulos; William Docken; Christina Duftner; Billy Fashanu; Kate Gilbert; Pamela Hildreth; Jane Hollywood; David Jayne; Manuella Lima; Ajesh Maharaj; Christian Mallen; Victor Martinez-Taboada; Mehrdad Maz; Steven Merry; Jean Miller; Shunsuke Mori; Lorna Neill; Elisabeth Nordborg; Jennifer Nott; Hannah Padbury; Colin Pease; Carlo Salvarani; Michael Schirmer; Wolfgang Schmidt; Robert Spiera; David Tronnier; Alexandre Wagner; Madeline Whitlock; Eric L Matteson; Bhaskar Dasgupta
Journal:  Ann Rheum Dis       Date:  2015-10       Impact factor: 19.103

Review 9.  Definition of remission and relapse in polymyalgia rheumatica: data from a literature search compared with a Delphi-based expert consensus.

Authors:  Christian Dejaco; Christina Duftner; Marco A Cimmino; Bhaskar Dasgupta; Carlo Salvarani; Cynthia S Crowson; Hilal Maradit-Kremers; Andrew Hutchings; Eric L Matteson; Michael Schirmer
Journal:  Ann Rheum Dis       Date:  2010-11-19       Impact factor: 19.103

  9 in total
  5 in total

1.  Long-term use of glucocorticoids for polymyalgia rheumatica: follow-up of the PMR Cohort Study.

Authors:  Sara Muller; Samantha L Hider; Balamrit Singh Sokhal; Sarah A Lawton; Toby Helliwell; Christian D Mallen
Journal:  Rheumatol Adv Pract       Date:  2022-05-11

2.  Examining management and research priorities in patients with polymyalgia rheumatica: a primary care questionnaire survey.

Authors:  Chris Morton; Sara Muller; Milica Bucknall; Kate Gilbert; Christian D Mallen; Samantha L Hider
Journal:  Clin Rheumatol       Date:  2019-01-07       Impact factor: 2.980

3.  What non-pharmacological treatments do people with polymyalgia rheumatica try: results from the PMR Cohort Study.

Authors:  Jake Weddell; Samantha L Hider; Christian D Mallen; Sara Muller
Journal:  Rheumatol Int       Date:  2021-10-22       Impact factor: 2.631

4.  Longitudinal clusters of pain and stiffness in polymyalgia rheumatica: 2-year results from the PMR Cohort Study.

Authors:  Sara Muller; Rebecca Whittle; Samantha L Hider; John Belcher; Toby Helliwell; Chris Morton; Emily Hughes; Sarah A Lawton; Christian D Mallen
Journal:  Rheumatology (Oxford)       Date:  2020-08-01       Impact factor: 7.580

5.  The availability of health information to patients with newly diagnosed polymyalgia rheumatica: results from the Polymyalgia Rheumatica (PMR) Cohort study.

Authors:  Maatla Tshimologo; Toby Helliwell; Samantha Hider; Christian Mallen; Sara Muller
Journal:  Prim Health Care Res Dev       Date:  2018-08-08       Impact factor: 1.458

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.